AbbVie Inc. (ABBV)

81.59
0.71 0.88
NYSE : Health Technology
Prev Close 80.88
Open 80.51
Day Low/High 79.88 / 81.75
52 Wk Low/High 75.62 / 107.24
Volume 4.22M
Avg Volume 5.70M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 117.47B
EPS 3.70
P/E Ratio 22.30
Div & Yield 4.28 (5.11%)
AbbVie To Showcase Scientific Innovation And Research Advancements Across Dermatology Portfolio At 2019 AAD Annual Meeting

AbbVie To Showcase Scientific Innovation And Research Advancements Across Dermatology Portfolio At 2019 AAD Annual Meeting

- Nineteen abstracts underscore AbbVie's continued pursuit of research on behalf of patients living with chronic dermatologic conditions

Voyager Shares Take Off on Parkinson's Disease Development Deal

Voyager Shares Take Off on Parkinson's Disease Development Deal

AbbVie to provide multi-million-dollar financing to Voyager to develop and commercialize potential Parkinson's treatment.

AbbVie And Voyager Therapeutics Announce Collaboration To Develop Vectorized Antibodies To Treat Parkinson's Disease And Other Synucleinopathies

AbbVie And Voyager Therapeutics Announce Collaboration To Develop Vectorized Antibodies To Treat Parkinson's Disease And Other Synucleinopathies

- Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Feb.

AbbVie Announces New Drug Application Accepted For Priority Review By U.S. FDA For Upadacitinib For Treatment Of Moderate To Severe Rheumatoid Arthritis

AbbVie Announces New Drug Application Accepted For Priority Review By U.S. FDA For Upadacitinib For Treatment Of Moderate To Severe Rheumatoid Arthritis

- Upadacitinib, an investigational once-daily oral JAK1-selective inhibitor, is being studied for the treatment of adult patients with moderate to severe rheumatoid arthritis[1-8]

AbbVie And Teneobio Announce A Strategic Transaction To Develop A New Treatment For Multiple Myeloma

AbbVie And Teneobio Announce A Strategic Transaction To Develop A New Treatment For Multiple Myeloma

NORTH CHICAGO, Ill. and MENLO PARK, Calif.

Johnson Fistel, LLP Announces Investigations Of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. And Uxin Limited; Investors Encouraged To Contact Firm

Johnson Fistel, LLP Announces Investigations Of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. And Uxin Limited; Investors Encouraged To Contact Firm

SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc.

Dividend Aristocrats Welcome a New Class of Nobility

Of the 57 index constituents, four Aristocrats have yields above 4.0%.

Watch Out for the Wave: Cramer's 'Mad Money' Recap (Tuesday 1/29/19)

Watch Out for the Wave: Cramer's 'Mad Money' Recap (Tuesday 1/29/19)

Jim Cramer says that if expectations are too high, even a great quarter cannot save you from the wave of selling.

Carvana, Bank OZK, Idexx Labs: 'Mad Money' Lightning Round

Carvana, Bank OZK, Idexx Labs: 'Mad Money' Lightning Round

Jim Cramer takes a look at Carvana, Bank OZK, Idexx Labs, Patterson-UTI Energy, 3D Systems, AbbVie and more.

Dow Closes Higher to End Week With Modest Gains

Dow Closes Higher to End Week With Modest Gains

Stocks rose by Friday's close, getting a boost from a number of strong corporate earnings reports even as investors continue to worry about a lack of progress in U.S.-China trade talks.

AbbVie Falls After Missing Top- and Bottom-Line Estimates

AbbVie Falls After Missing Top- and Bottom-Line Estimates

The pharmaceutical company reports fourth-quarter results below analysts' consensus forecasts.

Why Risk-On Is In Vogue, Updating Zuora: Market Recon

Why Risk-On Is In Vogue, Updating Zuora: Market Recon

China's central bank announced a bill swap mechanism late Thursday aimed at slowing down the nation's economic slowdown.

AbbVie Reports Full-Year And Fourth-Quarter 2018 Financial Results

AbbVie Reports Full-Year And Fourth-Quarter 2018 Financial Results

- Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent

AbbVie Provides Update On Phase 3 Study Of Ibrutinib (IMBRUVICA®) In Metastatic Pancreatic Cancer

AbbVie Provides Update On Phase 3 Study Of Ibrutinib (IMBRUVICA®) In Metastatic Pancreatic Cancer

-- The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Jim Cramer talks about the Fed, and outlines your game plan.

Qualcomm, Momo, Ciena: 'Mad Money' Lightning Round

Qualcomm, Momo, Ciena: 'Mad Money' Lightning Round

Jim Cramer weighs in on Qualcomm, Momo, Ciena, AbbVie, LM Ericsson and more.

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

AbbVie And Tizona Therapeutics Announce Strategic Collaboration To Develop First-in-Class Immunotherapy For Cancer Targeting CD39

AbbVie And Tizona Therapeutics Announce Strategic Collaboration To Develop First-in-Class Immunotherapy For Cancer Targeting CD39

- Initiation of clinical studies with TTX-030 is targeted in Q1 2019

AbbVie To Host Fourth-Quarter And Full-Year 2018 Earnings Conference Call

AbbVie To Host Fourth-Quarter And Full-Year 2018 Earnings Conference Call

NORTH CHICAGO, Ill., Jan.

3 Key Bear Market Rules, 5 Bargain Buys and a Monthly Dividend Portfolio

3 Key Bear Market Rules, 5 Bargain Buys and a Monthly Dividend Portfolio

Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.

AbbVie: The Perfect Stock for High Yield and Growth

ABBV offers an ideal mix of growth, value and income.

AbbVie Submits New Drug Application To U.S. FDA And Marketing Authorization Application To EMA For Upadacitinib For Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis

AbbVie Submits New Drug Application To U.S. FDA And Marketing Authorization Application To EMA For Upadacitinib For Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis

- Regulatory applications supported by robust SELECT Phase 3 program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis[1-5]

AbbVie To Present At The 37th Annual J.P. Morgan Healthcare Conference

AbbVie To Present At The 37th Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill., Dec.

AbbVie Announces Executive Leadership Changes

AbbVie Announces Executive Leadership Changes

NORTH CHICAGO, Ill., Dec.

AbbVie Announces $5 Billion Increase To Stock Repurchase Program

AbbVie Announces $5 Billion Increase To Stock Repurchase Program

NORTH CHICAGO, Ill., Dec.

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

As cannabis becomes more and more legal, investors have started to wonder what that means for them.

TheStreet Quant Rating: B- (Buy)